Radius Prices Osteoporosis 'Blockbuster' Tymlos To Compete, Grow Market

At $19,500 per year, Radius Health's Tymlos (abaloparatide) is priced to compete with Lilly's similar, but well-established drug Forteo. The company hopes to increase the size of the osteoporosis market to achieve its blockbuster sales goal, but at least one analyst has her doubts.